FDA Approves Novel Non-Opioid Painkiller Journavx
The FDA approved Vertex's non-opioid painkiller, Journavx, for moderate-to-severe acute pain, offering an addiction-free alternative impacting 80 million annual U.S. patients and potentially generating over $1 billion in annual sales.
FDA Approves Novel Non-Opioid Painkiller Journavx
The FDA approved Vertex's non-opioid painkiller, Journavx, for moderate-to-severe acute pain, offering an addiction-free alternative impacting 80 million annual U.S. patients and potentially generating over $1 billion in annual sales.
Progress
44% Bias Score
FDA Approves First New Non-Opioid Painkiller in Over 20 Years
The FDA approved Journavx (suzetrigine), a non-opioid painkiller, to treat moderate to severe acute pain in adults; clinical trials showed it reduced pain by 50% in 48 hours and is as effective as hydrocodone, but non-addictive.
FDA Approves First New Non-Opioid Painkiller in Over 20 Years
The FDA approved Journavx (suzetrigine), a non-opioid painkiller, to treat moderate to severe acute pain in adults; clinical trials showed it reduced pain by 50% in 48 hours and is as effective as hydrocodone, but non-addictive.
Progress
48% Bias Score
FDA Approves Non-Addictive Pain Pill Journavx
The U.S. Food and Drug Administration approved Vertex Pharmaceuticals' Journavx, a non-addictive pain medication, for short-term pain relief following surgery or injury; studies showed modest effectiveness compared to opioids, but its different mechanism offers a new approach, although its $15.50 pr...
FDA Approves Non-Addictive Pain Pill Journavx
The U.S. Food and Drug Administration approved Vertex Pharmaceuticals' Journavx, a non-addictive pain medication, for short-term pain relief following surgery or injury; studies showed modest effectiveness compared to opioids, but its different mechanism offers a new approach, although its $15.50 pr...
Progress
40% Bias Score
VRTX Stock Surges on Positive Casgevy Data and Analyst Upgrades
Vertex Pharmaceuticals (VRTX) stock price is surging due to positive long-term data for its gene therapy Casgevy and several bullish analyst upgrades, with Jefferies raising its price target to $550.00.
VRTX Stock Surges on Positive Casgevy Data and Analyst Upgrades
Vertex Pharmaceuticals (VRTX) stock price is surging due to positive long-term data for its gene therapy Casgevy and several bullish analyst upgrades, with Jefferies raising its price target to $550.00.
Progress
52% Bias Score